Evidence map›Paper›PMID 25625926›Full record

ReviewHuman vaccines & immunotherapeutics2014

Clinical trials of dendritic cell-based cancer vaccines in hematologic malignancies.

Athalia R Pyzer, David E Avigan, Jacalyn Rosenblatt

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Human vaccines & immunotherapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Interferon Gamma Secretion of Adaptive and Innate Immune Cells as a Parameter to Describe Leukaemia-Derived Dendritic-Cell-Mediated Immune Responses in Acute Myeloid Leukaemia in vitro.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2022
    Article
  6. Review
  7. Review
  8. Molecules (Basel, Switzerland) · 2021
    Article
  9. Review
  10. Dendritic Cells of Leukemic Origin: Specialized Antigen-Presenting Cells as Potential Treatment Tools for Patients with Myeloid Leukemia.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2020
    Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Cancer Immunotherapy: Beyond Checkpoint Blockade.Annual review of cancer biology · 2019
    Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Athalia R Pyzera Beth Israel Deaconess Medical Center; Harvard Medical School ; Boston , MA USA.
David E Avigan
Jacalyn Rosenblatt

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The potential for the immune system to target hematological malignancies is demonstrated in the allogeneic transplant setting, where durable responses can be achieved. However, allogeneic transplantation is associated with significant morbidity and mortality related to graft versus host disease. Cancer immunotherapy has the capacity to direct a specific cytotoxic immune response against cancer cells, particularly residual cancer cells, in order to reduce the likelihood of disease relapse in a more targeted and tolerated manner. Ex vivo dendritic cells can be primed in various ways to present tumor associated antigen to the immune system, in the context of co-stimulatory molecules, eliciting a tumor specific cytotoxic response in patients. Several approaches to prime dendritic cells and overcome the immunosuppressive microenvironment have been evaluated in pre-clinical and early clinical trials with promising results. In this review, we summarize the clinical data evaluating dendritic cell based vaccines for the treatment of hematological malignancies.

Indexed as

Antigens, NeoplasmCancer VaccinesClinical Trials as TopicDendritic CellsGraft vs Host DiseaseHematologic NeoplasmsHumansImmunotherapy, AdoptiveTransplantation, HomologousVaccinationAntigens, NeoplasmCancer VaccinesAML, Acute Myeloid LeukemiaApo-DC, Apoptotic body loaded- dendritic cellsASCT, Autologous Stem Cell TransplantcancerCML, Chronic Myeloid LeukemiaCR, Complete responseCTLA-4, Cytotoxic T-Lymphocyte Antigen 4DC/AML, Dendritic cell Acute Myeloid Leukemia fusion vaccineDC/MM, Dendritic cell Multiple Myeloma fusion vaccinedendritic cellDNA Deoxyribonucleic acidFLT-ITD, Fms-like Tyrosine Kinase with Internal Tandem DuplicationGMCSF, Granulocyte macrophage colony-stimulating factorGVHD, Graft vs Host DiseaseHLA-A*2402, Human Leukocyte antigen A*2402Id, IdiotypeIFNg, Interferon gammaIFN, InterferonIL, InterleukinimmunotherapyKLH, Keyhole limpet hemocyaninleukemiaMDS, Myelodysplastic syndromeMHC, Major histocompatibility complexmRNA, mRNAmyelomaOS, Overall SurvivalPD-1, Programmed death 1pDCs, Plasmacytoid Dendritic cellPD-L1, Programmed death-ligand 1PR, Partial responsePRR, Pathogen recognition receptorRNA, Ribonucleic acidSCT, Stem cell transplantTGFB, Transforming growth factor βTNFα, Tumor necrosis factor αtrialvaccineVEGF, Vascular endothelial growth factorVGPR, Very good partial responseWT-1, Wilm's tumor suppressor gene 1

Identifiers

PMID25625926
PMCPMC4514037

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.